Trials / Recruiting
RecruitingNCT06618651
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
Phase I Study of Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-3821 Injection in Subjects With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 162 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3821 injection in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-3821 injection | SHR-3821 injection |
Timeline
- Start date
- 2024-11-13
- Primary completion
- 2026-01-01
- Completion
- 2027-01-01
- First posted
- 2024-10-01
- Last updated
- 2025-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06618651. Inclusion in this directory is not an endorsement.